Home Cart Sign in  
Chemical Structure| 1346607-05-3 Chemical Structure| 1346607-05-3

Structure of GSK621
CAS No.: 1346607-05-3

Chemical Structure| 1346607-05-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

In AML cell lines and primary AML samples, GSK621 markedly increases phosphorylation at AMPKα T172, a marker of AMPK activation.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GSK621

CAS No. :1346607-05-3
Formula : C26H20ClN3O5
M.W : 489.91
SMILES Code : O=C1NC2=C(N(C3=CC=C(C4=CC=CC(OC)=C4O)C=C3)C(Cl)=C2)C(N1C5=CC=CC(OC)=C5)=O
MDL No. :MFCD28502280
InChI Key :KURYSXLJGKKDHT-UHFFFAOYSA-N
Pubchem ID :54577153

Safety of GSK621

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of GSK621

epigenetics
PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
OCI-AML2 cells 30 μM 24 hours CALR membrane exposure dependent on AMPK PMC10733104
MOLM14 cells 30 μM 24 hours CALR membrane exposure dependent on AMPK PMC10733104
MLL-AF9 cells 30 μM 48 hours Induced apoptosis and CALR membrane exposure PMC10733104
C1498 cells 30 μM 48 hours Induced apoptosis and CALR membrane exposure PMC10733104
Human umbilical cord vein endothelial cells (HUVEC) 10 μM 48 hours GSK621 inhibited ZIKV replication in HUVEC by activating AMPK α, evidenced by reduced viral antigen-positive cells and decreased viral titers. PMC7310572
Human retinal vascular endothelial cells (HRvEC) 10 μM 48 hours GSK621, a specific AMPK α activator, significantly inhibited ZIKV replication in HRvEC, as confirmed by immunostaining and viral titer determination. PMC7310572
Rat cardiac fibroblasts (CFs) 30 μM 48 hours To observe the effect of GSK621 on AMPK, it was found that GSK621 increased AMPK phosphorylation and reduced inflammation and fibrosis levels PMC8191636
Human primary erythroid progenitors 20 μM from day 0 after CD36+ selection to the indicated days To study the effect of GSK621 on erythroid differentiation, results showed that GSK621 significantly reduced the proliferation of mature erythroblasts and induced their apoptosis. PMC6518903
U87MG cells 10-100μM various time periods GSK621 inhibited U87MG cell survival in a concentration- and time-dependent manner and reduced the number of viable colonies. PMC4988667

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice AML model Subcutaneous injection 30 μM 24 hours treatment followed by fixation Induced immunogenic cell death and anti-cancer immune response PMC10733104

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.21mL

2.04mL

1.02mL

20.41mL

4.08mL

2.04mL

References

 

Historical Records

Categories